Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis

Busch, Howard; Wan, George J.; Niewoehner, John; Houston, Parul; Su, Yujie; Clinton, Cassie; Panaccio, Mary P

doi:10.7573/dic.2021-10-4

Cited by 2 publications

(4 citation statements)

References 44 publications

(85 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A claims database analysis indicated that Acthar was initiated in patients with RA who had more severe disease, comorbidities, and concomitant use of treatments including disease-modifying antirheumatic drugs (DMARDs), corticosteroids, opioids, and nonsteroidal anti-inflammatory drugs [ 35 ]. Real-world treatment patterns for patients with RA evaluated from medical records revealed that Acthar improved clinical outcomes and lowered the need for concomitant therapies up to 1 year after initiation of treatment [ 36 , 37 ]. Busch et al reported improvements in multiple RA disease assessments 12 months after Acthar initiation, as well as reductions in opioid, glucocorticoid, and nonsteroidal anti-inflammatory drug use; a small proportion (4.3%) of patients discontinued Acthar due to adverse effects (Table 1 ) [ 37 ].…”

Section: Clinical Studies Of Acthar: 2014–2022mentioning

confidence: 99%

“…Real-world treatment patterns for patients with RA evaluated from medical records revealed that Acthar improved clinical outcomes and lowered the need for concomitant therapies up to 1 year after initiation of treatment [ 36 , 37 ]. Busch et al reported improvements in multiple RA disease assessments 12 months after Acthar initiation, as well as reductions in opioid, glucocorticoid, and nonsteroidal anti-inflammatory drug use; a small proportion (4.3%) of patients discontinued Acthar due to adverse effects (Table 1 ) [ 37 ].…”

Section: Clinical Studies Of Acthar: 2014–2022mentioning

confidence: 99%

“…Busch et al reported improvements in multiple RA disease assessments 12 months after Acthar initiation, as well as reductions in opioid, glucocorticoid, and nonsteroidal anti-inflammatory drug use; a small proportion (4.3%) of patients discontinued Acthar due to adverse effects (Table 1 ) [ 37 ].…”

Section: Clinical Studies Of Acthar: 2014–2022mentioning

confidence: 99%

See 2 more Smart Citations

Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence

Kaplan,

Askanase,

Chu

et al. 2023

Clin Drug Investig

View full text Add to dashboard Cite

Acthar ® Gel (repository corticotropin injection) is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides that is believed to have both steroidogenic and nonsteroidogenic immunomodulatory effects via activation of melanocortin receptors in various cells throughout the body. Since 1952, Acthar has been approved by the US Food and Drug Administration to treat a variety of autoimmune and inflammatory diseases. Since 2014, Mallinckrodt Pharmaceuticals has conducted a large number of preclinical, clinical, and real-world-evidence studies of Acthar for the treatment of rheumatoid arthritis, systemic lupus erythematosus, dermatomyositis and polymyositis, multiple sclerosis relapse, ophthalmic disorders, sarcoidosis, and nephrotic syndrome. To date, Acthar has been the subject of more than 500 publications, many of which demonstrate the safety and efficacy of Acthar in patients with inflammatory diseases for whom standard treatments were ineffective or intolerable. Here, we review the history of Acthar and the findings of studies that have investigated the mechanism of action, safety, efficacy, and real-world effectiveness of Acthar for the treatment of inflammatory diseases. Supplementary Information The online version contains supplementary material available at 10.1007/s40261-023-01303-5.

show abstract

Section: Clinical Studies Of Acthar: 2014–2022mentioning

confidence: 99%

Section: Clinical Studies Of Acthar: 2014–2022mentioning

confidence: 99%

See 1 more Smart Citation

Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence

Kaplan,

Askanase,

Chu

et al. 2023

Clin Drug Investig

View full text Add to dashboard Cite

show abstract

“…2,34 Real-world effectiveness of RCI in patients with RA was evaluated in 3 separate studies from retrospective medical chart reviews of rheumatology practices. [35][36][37] In one study of RCI treatment patterns and physician impression of change among patients with RA, SLE, or DM/PM, 78% of RA patients (n=32) had a rating of "improved" on physicians' impression of change. 35 A retrospective analysis of electronic medical records data of patients with RA (n=114) found RCI was associated with clinically meaningful reductions in disease activity and severity, including significant improvements in joint swelling and tenderness as well as pain.…”

Section: Clinical Benefitsmentioning

confidence: 99%

Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence

Wan¹,

Niewoehner²,

Hayes³

2023

CEOR

Self Cite

View full text Add to dashboard Cite

Acthar ® Gel (repository corticotropin injection [RCI]) is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides used to treat patients with serious and rare inflammatory and autoimmune conditions. This narrative review summarizes the key clinical and economic findings among 9 indications: infantile spasms (IS), multiple sclerosis (MS) relapses, rheumatoid arthritis (RA), systemic lupus erythematosus (SLE), dermatomyositis and polymyositis (DM/PM), ocular inflammatory diseases (primarily uveitis and severe keratitis), symptomatic sarcoidosis, and proteinuria in nephrotic syndrome (NS). Key studies of clinical efficacy and healthcare resource utilization and cost from 1956 to 2022 are discussed. Evidence supports the efficacy of RCI across all 9 indications. RCI is recommended as first-line treatment for IS and is associated with improved outcomes for the other 8 indications, including increased recovery rates in MS relapse; improved disease control in RA, SLE, and DM/PM; realworld effectiveness in patients with uveitis and severe keratitis; improved lung function and reduced corticosteroid use in symptomatic sarcoidosis; and increased rates of partial remission of proteinuria in NS. For many indications, RCI may improve clinical outcomes during exacerbations or when conventional treatments have failed to show a benefit. RCI is also associated with a reduction in the use of biologics, corticosteroids, and disease-modifying antirheumatic drugs. Economic data suggest RCI is a cost-effective, value-based treatment option for MS relapse, RA, and SLE. Other economic benefits have been demonstrated for IS, MS relapses, RA, SLE, and DM/PM, including reduced hospitalizations, lengths of stay, inpatient and outpatient services, and emergency department visits. RCI is considered safe and effective and features economic benefits for numerous indications. Its ability to control relapse and disease activity makes RCI an important nonsteroid treatment option that could help preserve functioning and well-being among patients with inflammatory and autoimmune conditions.

show abstract

Real-world treatment patterns for repository corticotropin injection in patients with rheumatoid arthritis

Cited by 2 publications

References 44 publications

Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence

Acthar® Gel Treatment for Patients with Autoimmune and Inflammatory Diseases: An Historical Perspective and Characterization of Clinical Evidence

Acthar Gel (RCI): A Narrative Literature Review of Clinical and Economic Evidence

Contact Info

Product

Resources

About